Navigation Links
Delcath Announces Encouraging Top-Line Results From Hepatobiliary Cohort in Phase II Trial of Chemosaturation System
Date:8/22/2011

NEW YORK, Aug. 22, 2011 /PRNewswire/ -- Delcath Systems, Inc. (NASDAQ: DCTH) reported encouraging top-line results from the hepatobiliary cohort of the Phase II clinical trial of the Delcath chemosaturation system with melphalan in the treatment of patients with unresectable liver cancer. This study, conducted at the National Cancer Institute (USA), included four patient cohorts: hepatobiliary cancers, and metastatic cancers of neuroendocrine, ocular or cutaneous melanoma, and colorectal (adenocarcinoma) origins.  

There were nine patients with tumors of hepatobiliary origin: five hepatocellular carcinomas (HCC) and four cholangiocarcinomas.  HCC is the most common primary cancer of the liver, with approximately 500,000 new cases diagnosed worldwide annually. Both groups had positive efficacy signals. The responses were especially encouraging in the HCC cohort and consisted of confirmed partial response or durable stable disease.  The safety profile of the chemosaturation system was consistent with that previously reported for the Company's Phase 3 melanoma trial.

"The disease control and anti-tumor activity seen in the HCC arm of this Phase II study is very encouraging for primary liver cancer patients who currently face limited treatment options," said Eamonn P. Hobbs, President and CEO of Delcath System, Inc.  "We believe these results show a strong signal of efficacy, and support our plan to initiate Phase III and Phase IV trials for HCC in the second half of 2012."

Mr. Hobbs added, "We expect to announce additional data from this Phase II trial in the near future, and look forward to presenting detailed results from the metastatic neuroendocrine arm of this trial at the Cardiovascular and Interventional Radiological Society of Europe and European Society for Medical Oncology scientific meetings in September."

The trial's primary o
'/>"/>

SOURCE Delcath Systems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Delcath to Present at the Wedbush 2011 Life Sciences Conference on August 16, 2011
2. Delcath Systems to Report Second Quarter Progress Update and Conduct Conference Call
3. Delcath Systems, Inc. Announces the Completion of Common Stock Offering
4. Delcath Systems, Inc. Announces the Sale of 5,000,000 Shares of Common Stock
5. Delcath on Preliminary List of Additions to Russell Microcap® Index
6. Delcath to Present at the JMP Securities Research Conference
7. Delcath Names Harold C. Mapes as Executive Vice President of Global Operations
8. Delcath Receives Notice of European Regulatory Approval for Hepatic CHEMOSAT™ Delivery System
9. Delcath to Update Investors on FDA Meeting
10. Delcath Expands Board of Directors With Appointment of Gabriel Leung
11. Delcath to Present at Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... LOUISVILLE, Ky. , Jan. 15, 2014  Manufacturers, ... technologies must be able to protect their most ... (Logo: http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) Because ... Industry, it steadfastly remains one of the most ...
(Date:1/15/2014)...  Echo Therapeutics, Inc. (Nasdaq: ECTE ) ("Echo"), ... as a non-invasive, wireless continuous glucose monitoring system, today ... and Interim CEO of Echo Therapeutics, will present at ... Mr. Doman will make a corporate ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com announces ... available in its catalogue: ... Forecast and Market Analysis to 2022 ... Atopic Dermatitis - India Drug Forecast and ...
Breaking Medicine Technology:Intellectual Property Insurance for Medical-related Products and Services 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5
... Vycor Medical, Inc. ("Vycor" or the "Company") has ... quarter ended March 31, 2011, the year ended December ... June 30, 2010 and September 30, 2010 and the ... periodic reports filed with the Securities and Exchange Commission ...
... On Friday, August 19, veterinary cardiologists are going to ... Dog Heart Health Tour will stop with a soundproof ... Bark Park in Ridgefield, Conn. (Photo:   ... free heart health screenings, veterinarians will be available to ...
Cached Medicine Technology:Vycor Medical, Inc. Restatement of Financial Statements 2Vycor Medical, Inc. Restatement of Financial Statements 3Free Dog Heart Health Screenings Available August 19 in Connecticut 2
(Date:4/17/2014)... Men who show signs of chronic inflammation in non-cancerous ... actually having prostate cancer than those with no inflammation, ... researchers from the Johns Hopkins Kimmel Cancer Center. , ... stronger for men with so-called high-grade prostate cancer ... indicating the presence of the most aggressive and ...
(Date:4/17/2014)... vaccine brands for children may not be the most ... factors when choosing vaccines, driving the market toward what ... new study by University of Illinois researchers. , "The ... numerous factors," says Sheldon H. Jacobson, a co-author of ... of mathematics at the U. of I. "In an ...
(Date:4/17/2014)... School of Medicine report that older women, plucky individuals ... are more likely to be compassionate toward strangers than ... this month,s issue of the International Journal of ... with better health and well-being as we age, the ... outcomes of individuals whose deficits in compassion put them ...
(Date:4/17/2014)... Hospital Pediatrician-in-Chief Jon McCullers, MD, was recently invited ... of Nature Reviews Microbiology , one of ... a world-renowned infectious disease specialist, and chair of ... Tennessee Health Science Center, analyzed the epidemiology and ... 1968 pandemics, as well as more recent 2009 ...
(Date:4/17/2014)... (April 17, 2014) Doctors who treat patients ... lymphangioleiomyomatosis (LAM) can face an agonizing treatment decision. ... the disease and help relieve shortness of breath. ... and sirolimus can cause potentially fatal complications following ... Dr. Daniel Dilling, medical director of Loyola University ...
Breaking Medicine News(10 mins):Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:Study recalculates costs of combination vaccines 2Health News:The ilk of human kindness 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3
... Ten Big Brothers Big Sisters agencies will receive the 2009 ... as partners" to help children improve their odds for success. ... the nation,s largest donor-supported volunteer mentoring network with nearly 400 ... with a focus on breaking negative cycles. Big Brothers ...
... LCGC North America is pleased to announce the full ... The program, in its second year, will be co-chaired by ... and David Walsh, Editor-in-Chief, LCGC North America . The ... 2009. , , LCGC,s speaker faculty ...
... , , ... Board: NWCI) a cardiac diagnostic and services company, today announced ... Services Agreement (MSA) to use NewCardio,s QTinno(TM) software suite as ... 1 studies delivered by its centralized ECG core lab. NewCardio ...
... ... California sleep apnea expert, has found a way to help patients win the battle against ... treatment they need. , ... Angeles, CA (PRWEB) August 27, 2009 -- Dr. Jonathan Greenburg, a Southern California sleep apnea ...
... ... Announcing an exciting innovation in antimicrobial coatings: OxiTitan ... with the power of light. Durable and easily applied to existing ... effective indoors, utilizing normal incandescent or flourescent lighting. The continuously active ...
... ... technology advances to reduce operating costs and improve efficiencies for homecare providers. ... ... enhancements designed to improve productivity for homecare providers., , , , ,According to ...
Cached Medicine News:Health News:10 Big Brothers Big Sisters Agencies to Receive 2009 Annie E. Casey Family Strengthening Award 2Health News:10 Big Brothers Big Sisters Agencies to Receive 2009 Annie E. Casey Family Strengthening Award 3Health News:LCGC Announces the Agenda for Their Upcoming PharmSep Conference 2Health News:NewCardio Announces Master Services Agreement With Top-Three Contract Research Organization 2Health News:NewCardio Announces Master Services Agreement With Top-Three Contract Research Organization 3Health News:NewCardio Announces Master Services Agreement With Top-Three Contract Research Organization 4Health News:Sleep Apnea Expert Offers Incentives That Could Save Lives 2Health News:Sleep Apnea Expert Offers Incentives That Could Save Lives 3Health News:EcoActive Surfaces Introduces OxiTitan VLR: New Light Powered Antimicrobial Coating Effective Against Viruses and Bacteria Indoors 2Health News:EcoActive Surfaces Introduces OxiTitan VLR: New Light Powered Antimicrobial Coating Effective Against Viruses and Bacteria Indoors 3Health News:New Fastrack Technology Improves Productivity 2Health News:New Fastrack Technology Improves Productivity 3
... Conduit TCP is a synthetic porous ceramic graft ... to the mineral phase that comprises 70% of ... provides a scaffold that allows the attachment of ... of vascular networks within granules as well as ...
... an osteoconductive matrix constructed of cross-linked ... with hydroxyapatite through a proprietary 360 ... bone marrow aspirate, Healos provides an ... proliferation and differentiation. The hydroxyapatite-coated collagen ...
Blunt Weitlaner Retractor....
Beckman-Weitlaner retractor, blunt, with hinged arms, 6 1/2"....
Medicine Products: